Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma

Published:2024-06 Issue:6 Volume:5 Page:101584
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Van Oekelen Oliver^ORCID,Amatangelo Michael,Guo Manman,Upadhyaya Bhaskar,Cribbs Adam P.,Kelly Geoffrey,Patel Manishkumar,Kim-Schulze Seunghee,Flynt Erin,Lagana Alessandro,Gooding Sarah,Merad Miriam,Jagganath Sundar,Pierceall William E.,Oppermann Udo,Thakurta Anjan,Parekh Samir

Publisher

Elsevier BV

Reference49 articles.

1. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis;McCarthy;J. Clin. Oncol.,2017

2. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study;Richardson;Blood,2014

3. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma;Benboubker;N. Engl. J. Med.,2014

4. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial;Miguel;Lancet Oncol.,2013

5. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial;Rajkumar;Lancet Oncol.,2010

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacodynamic changes in tumor and immune cells drive iberdomide’s clinical mechanisms of activity in relapsed and refractory multiple myeloma;Cell Reports Medicine;2024-06